5 ms·
>It appears as if this isn't the first time Theranos has butted heads with FDA inspectors: "This document was provided as a follow-up to the failures in your de
by epistasis 11y ago
>It appears as if this isn't the first time Theranos has butted heads with FDA inspectors: "This document was provided as a follow-up to the failures in your design validation conducted in 2014," the FDA report says.
$10 billion valuation, and this is the best they can do?
It seems like silly season is going to end soon. This time there are a lot of solid businesses in the valley with solid revenue and solving real problems. Then there are the dilettantes and the scammers. All will be revealed as it becomes more difficult to raise money.
- venomsnake 11y agoWhile current interest rates are below zero effectively - the raising money will be as easy.
- ryporter 11y agoThey may still actually have an real innovation (we need more evidence), but I do agree that this is a massive failure for such a valuable company. After the huge setback that 23AndMe suffered from their run-in with the FDA, every well-funded company under their jurisdiction should be triple-checking everything related to FDA compliance, since it poses such a grave, existential risk.
- deleted 11y ago[deleted]
- a_bonobo 11y agoInterestingly, both 23andMe and Theranos just sat on the documents issued to them by the FDA, see https://news.ycombinator.com/item?id=10462936 https://news.ycombinator.com/item?id=10462936 Do both have the same guy working on FDA-approval?
- adventured 11y agoIt's the Uber aggressive approach - break the rules, try to get big faster than they can slow you down - applied to something directly ruled by a federal bureaucracy. That'll never turn out well. With the FDA you have to play the game the way they want you to or they'll instantly nuke your operation. The Uber approach only works if you're dealing with lots of little bureaucracies.